Skip to main content
Equibles
LLY logo

LLY · ELI LILLY & Co

Track LLY — free

Use LLY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LLY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1,145.09 -7.35 (-0.64%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$1.07T
Shares
941.36M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1,152.44 Open$1,150.27 Day$1,138.26–1,159.75 52W close$714.59–1,280.34 Avg vol 30d2.4M Short int7.9M · 0.8% float · 3.0d Short vol43% Last earningsOct 29, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Oct 29, 2026 Scheduled · in 6 wks
Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$79.67B
Trailing 12 months
Net income (TTM)
$26.71B
Trailing 12 months
Revenue growth YoY
+47.7%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
38.2
Trailing earnings · reciprocal yield 2.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
+48.8%
Trailing year
Short interest
0.8%
Latest settlement · 3.0 days to cover
View all 115 metrics

Equibles Research

our published analysis of this company

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 15.4 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg −2%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 77%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +28%
trailing
YTD return +7%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1179 › 200d $1066 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +413 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.84% of float · ▲ +20.3% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
4,652 holders — near 3-yr high, broad support
Squeeze score 49
elevated · 0–100
Fundamentals
Strong
Revenue growth +45%
Y/Y
EPS growth +96%
Y/Y
Valuation P/E 38.2
in line
Buyback $7.0B
remaining
Balance sheet $35.2B
net debt
Quant / Vol
risk profile
Moderate
Volatility 36%
annualized · 1-yr
Max drawdown −23%
past year
ATR 2.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 3
Latest guidance · from the Earnings Call filed Aug 5, 2026
Non-GAAP performance margin · full year 2026 Non-GAAP Initiated 49% – 50.5%
Non-GAAP earnings per share · full year 2026 Non-GAAP Initiated $35.50 – $36.50
Prior guidance period ended · from the 8-K filed Aug 8, 2024
(Gross Margin - OPEX) / Revenue (reported) · 2024 full-year 36% – 38%
(Gross Margin - OPEX) / Revenue (non-GAAP) · 2024 full-year 37% – 39%
Other Income/(Expense) (non-GAAP) · 2024 full-year $-400M – $-300M
Other Income/(Expense) (reported) · 2024 full-year $-525M – $-425M
Tax Rate · 2024 full-year 15%
Earnings per Share (reported) · 2024 $13.05 – $13.55
Earnings per Share (non-GAAP) · 2024 $13.50 – $14.00
Guided vs delivered · last 3 settled
Earnings per Share (reported) 2024
guided $13.05 – $13.55
$11.71 Miss −12.0%
Revenue full-year 2021
guided $27.2B – $27.6B
$28.32B Beat +3.4%
GAAP EPS full year 2020
guided $6.20 – $6.40
$6.79 Beat +7.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
−2% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
77% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1179 › 200d $1066 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +413 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.84% of float · ▲ +20.3% MoM · 3.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
4,652 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $715 Now $1,152 · 77% Range high $1,280
vs 200-day avg +8% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LLY
ELI LILLY & Co
this stock
$1.07T +7.2% +44.7% 38.2 0.8%
JNJ
Johnson & Johnson
 $641.80B +30.6% +6.0% 30.9 0.9%
ABBV
AbbVie Inc.
 $464.82B +15.5% +8.6% 74.3 1.1%
MRK
Merck & Co., Inc.
 $357.37B +39.8% +1.3% 115.9 1.2%
NVS
Novartis AG
 $264.18B +2.2% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
4,652
% held
86.7%
Net QoQ
+19.7M sh
Top holder
LILLY ENDOWMENT INC
Held Float
View
Held by Funds
Fund positions
1,841
View
Short & Settlement
Short Interest Rising
Shares short
7.9M
Days to cover
3.0d
Change
+1.3M sh
View
Short Volume
Short vol %
43%
As of
Sep 17, 2026
Short Total
View
Fails to Deliver
FTD shares
85
Value
$99.8K
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
46.8%
Week of
Aug 10, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Dan Newhouse
Amount
$1.0K–$15.0K
Traded
Jul 10, 2026
View
Financials
Financials
Revenue (FY)
$65.2B
Net income (FY)
$20.6B
EPS diluted
$22.95
View
Buybacks
Authorized
$15.0B
Remaining
$7.0B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
9
View
Proposed Sales
Value
$2.4M
Shares
2.0K
Filed
Aug 10, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Oct 29, 2026
Last call
Aug 5, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
LLY +2.6% -10.0% +28.5% -0.4% +7.2%
SPY +0.6% -0.8% +18.2% -0.6% +11.8%
vs SPY +2.0% -9.2% +10.3% +0.2% -4.6%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$15.00B
Spent (derived)
$8.00B
Remaining
$7.00B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 59478 CUSIP 532457108 13F (30d) 137 filings 80 filers Visit website Investor relations